Early data from a study in Botswana has shown an increased risk in neural tube defects in babies born to mothers taking dolutegravir during pregnancy, prompting worldwide warnings against its use in pregnancy and women of child-bearing age.

The NEJM blog published an informative piece on why the information is important, and what we need to do about it